

Neocarzinostatin versus m-AMSA or doxorubicin in hep

Journal of Clinical Oncology

2, 581-584

DOI: 10.1200/jco.1984.2.6.581

Citation Report

#	ARTICLE	IF	CITATIONS
1	Phase II studies of mitoxantrone in patients with primary liver cancer. <i>Investigational New Drugs</i> , 1985, 3, 187-9.	2.6	14
2	4'Epidoxorubicin (epirubicin): activity in hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 1985, 3, 1535-1540.	1.6	79
3	Hepatitis-B as a prognostic discriminant in patients with primary liver cancer. <i>Cancer</i> , 1986, 57, 812-815.	4.1	7
4	Amsacrine: A review. <i>Leukemia Research</i> , 1986, 10, 1257-1265.	0.8	39
5	A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma: An ECOG study. <i>Cancer</i> , 1987, 60, 2141-2145.	4.1	92
6	Clinical trials in primary hepatocellular carcinoma: current status and future directions. <i>Cancer Treatment Reviews</i> , 1988, 15, 1-31.	7.7	196
7	Controlled Therapeutic Trials for Malignant Hepatoma: Overlooked Studies. <i>Annals of Internal Medicine</i> , 1988, 109, 681.	3.9	2
8	Differential Neutralizing Effect of Tiopronin on the Toxicity of Neocarzinostatin and SMANCS: A New Rescue Cancer Chemotherapy. <i>Japanese Journal of Cancer Research</i> , 1989, 80, 394-399.	1.7	4
9	A prospective trial of recombinant human interferon alpha 2B in previously untreated patients with hepatocellular carcinoma. <i>Cancer</i> , 1990, 66, 135-139.	4.1	67
11	Crystal structure of neocarzinostatin, an antitumor protein-chromophore complex. <i>Science</i> , 1993, 262, 1042-1046.	12.6	87
12	Medical Treatment of Hepatocellular Carcinoma: Any Progress?. <i>Tumori</i> , 1994, 80, 315-326.	1.1	19
13	Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials. <i>Annals of Oncology</i> , 1997, 8, 117-136.	1.2	341
14	Review article: overview of medical treatments in unresectable hepatocellular carcinomaâ€”an impossible metaâ€”analysis?. <i>Alimentary Pharmacology and Therapeutics</i> , 1998, 12, 111-126.	3.7	150
15	Practical Considerations in the Treatment of Hepatocellular Carcinoma. <i>Drugs</i> , 1998, 55, 367-382.	10.9	23
16	Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2001, 85, 1850-1852.	6.4	36
17	Randomized Clinical Trials in Hepatocellular Carcinoma and Biliary Cancer. <i>Surgical Oncology Clinics of North America</i> , 2002, 11, 193-205.	1.5	6
18	Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. <i>Hepatology</i> , 2003, 37, 429-442.	7.3	2,646
19	Systemic therapies for hepatocellular carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 1555-1568.	4.1	48

#	ARTICLE	IF	CITATIONS
20	Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. <i>Lancet Oncology</i> , The, 2004, 5, 409-418.	10.7	143
21	Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials: systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinoma. <i>Anti-Cancer Drugs</i> , 2004, 15, 439-452.	1.4	57
22	Regional and Systemic Chemotherapy for Primary Hepatobiliary Cancers and for Colorectal Cancer Metastatic to the Liver. <i>Seminars in Radiation Oncology</i> , 2005, 15, 284-298.	2.2	18
23	Phase III Randomized Controlled Trial Comparing the Survival of Patients With Unresectable Hepatocellular Carcinoma Treated With Nilotrexed or Doxorubicin. <i>Journal of Clinical Oncology</i> , 2007, 25, 3069-3075.	1.6	249
24	Review: the treatment of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 1988, 2, 187-201.	3.7	4
25	Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada. <i>Current Medical Research and Opinion</i> , 2008, 24, 3559-3569.	1.9	26
26	Hepatocellular Carcinoma: ., 2011, , .		4
27	Nano-Sized Drug Delivery Systems: Development and Implication in Treatment of Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2015, 33, 675-682.	1.9	8
28	Hepatocellular carcinoma. <i>Cancer Treatment and Research</i> , 1998, 98, 83-109.	0.5	1
29	Medical Therapy of HCC. , 2016, , 489-512.		1
30	Die systemische Chemotherapie des Leberkarzinoms. , 1991, , 31-46.		1
31	Chemotherapy of Primary Liver Cancer. , 1987, , 321-326.		7
32	Human Central Nervous System Pharmacology of Antineoplastic Agents: Implications for the Treatment of Brain Tumors. , 1987, , 387-395.		3
33	Glutathione depletion greatly reduces neocarzinostatin cytotoxicity in Chinese hamster V79 cells.. <i>Journal of Biological Chemistry</i> , 1985, 260, 8312-8315.	3.4	32
34	Medical Treatment of Hepatocellular Carcinoma. <i>Gastroenterology Clinics of North America</i> , 1987, 16, 603-612.	2.2	28
36	è,ç™CEã®æ²»ç™,ã•ã°é~2-æœ€è¿‘ã®é€²æ©- 3. è,ã«è,,^ã†...æ³”ã...ÿç™,æ³•. <i>Acta Hepatologica Japonica</i> , 2002, 43, 258-265.		1
37	HepatozellÃres Karzinom (HCC). , 2006, , 4045-4070.		0
38	Medical Therapy of HCC. , 2009, , 527-568.		0

#	ARTICLE	IF	CITATIONS
39	Cytotoxic Chemotherapy and Endocrine Therapy for Hepatocellular Carcinoma. , 2011, , 337-353.		0
40	Medical Management Options for Hepatocellular Carcinoma. , 0, , .		0
41	Natural History of Liver Cancer. , 1985, , 21-31.		0
42	New Chemotherapeutic Agents in Liver Cancer. , 1985, , 217-224.		0
43	Regionale Therapie bei hepatozellulÄrem Karzinom. , 1991, , 121-131.		0
44	Medical Therapy of Hepatocellular Carcinoma. , 2005, , 233-264.		0